{"name":"ASTRAZENECA AB","slug":"astrazeneca-ab","ticker":"","exchange":"","domain":"astrazenecaab.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Wainua first approved","drug":"Wainua","drugSlug":"eplontersen","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-13","label":"TEZSPIRE Phase 3 readout (Chronic Rhinosinusitis With Nasal Polyps)","drug":"TEZSPIRE","drugSlug":"tezepelumab-ekko","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-25","label":"TEZSPIRE Phase 3 readout (Severe Asthma)","drug":"TEZSPIRE","drugSlug":"tezepelumab-ekko","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-04-01","label":"IMJUDO Phase 3 readout (Non Small Cell Lung Cancer, NSCLC, Stage III)","drug":"IMJUDO","drugSlug":"tremelimumab-actl","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-01-26","label":"SAPHNELO Phase 3 readout (Systemic Lupus Erythematosus)","drug":"SAPHNELO","drugSlug":"anifrolumab-fnia","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-03-10","label":"IMJUDO Phase 3 readout (Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8)","drug":"IMJUDO","drugSlug":"tremelimumab-actl","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-08-18","label":"TEZSPIRE Phase 3 readout (Severe Asthma, Allergy to House Dust Mites)","drug":"TEZSPIRE","drugSlug":"tezepelumab-ekko","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-12-01","label":"TEZSPIRE Phase 3 readout (Asthma)","drug":"TEZSPIRE","drugSlug":"tezepelumab-ekko","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"BEYFORTUS","genericName":"NIRSEVIMAB-ALIP","slug":"nirsevimab-alip","indication":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","status":"marketed"},{"name":"TEZSPIRE","genericName":"TEZEPELUMAB-EKKO","slug":"tezepelumab-ekko","indication":"Severe asthma","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Symlin","genericName":"PRAMLINTIDE","slug":"pramlintide","indication":"Type 1 Diabetes Mellitus Treatment Adjunct","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DAPA","genericName":"DAPA","slug":"dapa","indication":"Chronic heart failure","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Wainua","genericName":"EPLONTERSEN","slug":"eplontersen","indication":"Polyneuropathy of hereditary transthyretin-mediated amyloidosis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"IMJUDO","genericName":"TREMELIMUMAB-ACTL","slug":"tremelimumab-actl","indication":"Liver cell carcinoma","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"SAPHNELO","genericName":"ANIFROLUMAB-FNIA","slug":"anifrolumab-fnia","indication":"Moderate to severe systemic lupus erythematosus (SLE)","status":"marketed"}]}],"pipeline":[{"name":"Symlin","genericName":"PRAMLINTIDE","slug":"pramlintide","phase":"marketed","mechanism":"Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3","indications":["Type 1 Diabetes Mellitus Treatment Adjunct","Type 2 Diabetes Mellitus Treatment Adjunct"],"catalyst":""},{"name":"DAPA","genericName":"DAPA","slug":"dapa","phase":"marketed","mechanism":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","indications":["Chronic heart failure","Chronic kidney disease","Diabetes mellitus type 1","Diabetes mellitus type 2"],"catalyst":""},{"name":"Wainua","genericName":"EPLONTERSEN","slug":"eplontersen","phase":"marketed","mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein.","indications":["Polyneuropathy of hereditary transthyretin-mediated amyloidosis"],"catalyst":""},{"name":"BEYFORTUS","genericName":"NIRSEVIMAB-ALIP","slug":"nirsevimab-alip","phase":"marketed","mechanism":"Fusion glycoprotein F0","indications":["Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease"],"catalyst":""},{"name":"IMJUDO","genericName":"TREMELIMUMAB-ACTL","slug":"tremelimumab-actl","phase":"marketed","mechanism":"Cytotoxic T-lymphocyte protein 4","indications":["Liver cell carcinoma","Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","Non-small cell lung cancer, negative for epidermal growth factor receptor expression"],"catalyst":""},{"name":"SAPHNELO","genericName":"ANIFROLUMAB-FNIA","slug":"anifrolumab-fnia","phase":"marketed","mechanism":"Interferon alpha/beta receptor 1","indications":["Moderate to severe systemic lupus erythematosus (SLE)"],"catalyst":""},{"name":"TEZSPIRE","genericName":"TEZEPELUMAB-EKKO","slug":"tezepelumab-ekko","phase":"marketed","mechanism":"Thymic stromal lymphopoietin","indications":["Severe asthma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":7,"phaseCounts":{"marketed":7},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}